--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ORKA20260220C35
Biological Technology
Oruka Therapeutics, Inc. Completed the Business Combination (Merger) with ARCA Colorado under the terms of the Agreement and Plan of Merger and Reorganization dated September 24, 2008, as amended on October 28, 2008, wherein a wholly-owned subsidiary of Nuvelo, Inc., merged with ARCA Colorado, ARCA Colorado continues as the surviving company and a wholly-owned subsidiary of Nuvelo, Inc. Immediately following the merger, the company changed its name from Nuvelo, Inc. to ARCA Biopharma, Inc. Nuvelo was originally incorporated as HYSEQ. The company is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapies for psoriasis, inflammation and immunological indications.
